Search tips
Search criteria

Results 1-8 (8)

Clipboard (0)
more »
Year of Publication
1.  Proposed ban on mercury may hit Ayurveda adversely 
Ayu  2013;34(1):2-3.
PMCID: PMC3764874  PMID: 24049396
2.  Ethical prescription writing in Ayurveda 
Ayu  2012;33(1):3-4.
PMCID: PMC3456859  PMID: 23049175
3.  A survey on etiopathological correlation of Krimi (intestinal helminths) and Pandu (anemia) 
Ayu  2011;32(2):165-170.
A survey study was aimed to find etiopathological status of intestinal helminths and also to accomplish its association with clinical condition Pandu. The survey samples included population of five schools and two localities in and around Jamnagar. The study was conducted on 337 subjects, of whom 36.20% cooperated to give stool samples to pathology laboratory; more than half of the samples surveyed were suffering with various parasitic infestations and one-third of the total subjects were found at risk to develop Pandu. Ascariasis patients were found in 71.14%, a potent cause of Pandu. Enterobius vermicularis was found in 19.05%, while Hymenolepis nana in 6.35%. 77.77% were in the age group of 10 to 20 years, 58.73% were male, 93.65% patients were Hindu, 80.95% of the patients had secondary level of education, dominancy of rural habitat was in 77.77%, and 39.68% each were from lower and lower middle class.
PMCID: PMC3296334  PMID: 22408296
Intestinal helminths; Pandu; Ascariasis; Udara Krimi
4.  Need of new research methodology for Ayurveda 
Ayu  2011;32(1):3-4.
PMCID: PMC3215413  PMID: 22131749
5.  Efficacy of Rasayana Avaleha as adjuvant to radiotherapy and chemotherapy in reducing adverse effects 
Ayu  2010;31(4):417-423.
Cancer is the most dreadful disease affecting mankind. The available treatments such as chemotherapy and radiotherapy have cytotoxic effects, which are hazardous to the normal cells of the patient, causing many unnecessary effects. This further leads to complications of the therapy, impaired health, and deterioration of quality of life, resulting in mandatory stoppage of the treatment. In the present study, the efficacy of an Ayurvedic formulation, Rasayana Avaleha, has been evaluated as an adjuvant medication to modern radiotherapy and chemotherapy. A total of 36 cancer patients were registered in this trial and were divided into two groups, group A and group B. In group A, the patients were treated with radiotherapy and chemotherapy along with adjuvant Rasayana Avaleha (RT + CT + RA), while in group B only radiotherapy and chemotherapy (RT + CT) were given, as the control group. After assessing the results, it was observed that Rasayana Avaleha gave better results in controlling the adverse effect of chemotherapy and radiotherapy in comparison with the control group. Therefore, Rasayana Avaleha has proved to be an effective adjuvant therapy in protecting patients from the adverse effects of chemotherapy and radiotherapy.
PMCID: PMC3202271  PMID: 22048532
Cancer; Radiotherapy; Chemotherapy; Adverse Effects; Ayurveda; Rasayana Avaleha
6.  Randomized placebo-controlled trial of Mustadi Ghanavati in hyperlipidemia 
Ayu  2010;31(3):287-293.
Hyperlipidemia is one of the major lifestyle disorders. Its role has been appreciated in the manifestation of serious diseases like ischemic heart disease, diabetes, stroke etc. These lifestyle diseases are a result of lifestyle factors such as overnutrition etc., which have been referred to as the Santarpanjanya Vyadhis in the classical texts. Mustadi Ghanavti is a modified form of the classical formulation Mustadi Kwath that has been advocated by Acharya Charaka for the management of Santarpanjanya Vikaras. This placebo-controlled randomized trial of Mustadi Ghanavati was carried out on 61 patients suffering from hyperlipidemia; of the 61 patients, 50 completed the entire course of treatment. The results of the study revealed that Mustadi Ghanavati decreased serum cholesterol by 22.4%, serum triglycerides by 19.6%, serum LDL by 18.2%, and serum VLDL by 4.2%; serum HDL increased by 5.6%. Thus Mustadi Ghanavati was able to effect a total improvement of 58.8% in the lipid profile. It brought about mild improvement in 42.86% of patients and moderate improvement in 14.28% of patients. Mustadi Ghanavati was also found to have a significant effect on other subjective as well as objective parameters considered for the study.
PMCID: PMC3221060  PMID: 22131728
Hyperlipidemia; Mustadi Ghanavati; placebo-controlled trial
7.  A clinical comparative study of the management of chronic renal failure with Punarnavadi compound 
Ayu  2010;31(2):185-192.
India like any other country is facing a silent epidemic of chronic renal failure (CRF)- a facet of the health transition associated with industrialization partly fuelled by increase in sedentary lifestyle, low birth weight and malnutrition. Increasing figures by many folds seen is posing a difficult situation to overcome with respect to economy and health of the working and earning population of the nation. There is an urgent need to explore, highlight new interventions and modify modifiable risk factors as a basis for treatment strategies to prevent the development and progression of CRF. The present study was taken up to evaluate the role of trial formulation tab. Punarnavadi compound in the management of chronic renal failure. This was an open clinical comparative study in controlled circumstances wherein 67 patients were studied for two months in three groups- Group A (allopathic control), Group B (ayurvedic control) and Group C (ayurvedic test). It was a multi-centric study; patients were registered from Anandababa charitable dialysis centre, Jamnagar, Kayachikitsa O.P.D. of I.P.G.T. and R.A. Jamnagar and P. D. Patel Ayurveda hospital, Nadiad. Results were assessed on 15 parameters using Students (paired) ‘t’ test. Group A patients showed comparatively better results in eight parameters- weight, platelet count, serum urea, serum uric acid, serum sodium, potassium, chloride and total proteins. Parameter Hemoglobin% showed better results in Group B patients and in Group C patients comparatively better results in six parameters viz.- quality of life (breathlessness, weakness, general functional capacity), total count, serum creatinine and serum calcium - were observed. Throughout the study, trial drug tab. Punarnavadi compound did not show any adverse drug reaction. The results of this study will help in developing a cheap and safe treatment for the management of CRF.
PMCID: PMC3215362  PMID: 22131708
Chronic kidney disease; chronic renal failure; Punarnavadi compound; ayurvedic management.
8.  Prajwalito Dnyanamayah Pradeepah… 
Ayu  2010;31(1):I.
PMCID: PMC3215331  PMID: 22131697

Results 1-8 (8)